Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical Co's cash flow for dividends for the
three
months ended in Jun. 2026 was $0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Jun. 2026 was $-2,915 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Chugai Pharmaceutical Co's quarterly payment of dividends
increased
from Dec. 2025 ($1 Mil) to Mar. 2026 ($-1,525 Mil) but then
declined
from Mar. 2026 ($-1,525 Mil) to Jun. 2026 ($0 Mil).
Chugai Pharmaceutical Co's annual payment of dividends
declined
from Dec. 2023 ($-914 Mil) to Dec. 2024 ($-866 Mil) but then
increased
from Dec. 2024 ($-866 Mil) to Dec. 2025 ($-1,920 Mil).
Chugai Pharmaceutical Co Cash Flow for Dividends Related Terms
Chugai Pharmaceutical Co Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Chugai Pharmaceutical Co's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Cash Flow for Dividends Chart
Chugai Pharmaceutical Co Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,915 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of $-2,915 Mil mean?
Chugai Pharmaceutical Co (CHGCF) has a Cash Flow for Dividends of $-2,915 Mil as of Jun. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Cash Flow for Dividends too high?
Chugai Pharmaceutical Co's current Cash Flow for Dividends is $-2,915 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Cash Flow for Dividends compare to LLY and JNJ?
Chugai Pharmaceutical Co's Cash Flow for Dividends of $-2,915 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Cash Flow for Dividends is $-2,915 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $49.32, compared to a current price of $43.18 — trading 12.4% below its estimated fair value. The current Cash Flow for Dividends is $-2,915 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Cash Flow for Dividends is $-2,915 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $43.18 is trading 12.4% below its estimated GF Value™ of $49.32.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCF:
Cash Flow for Dividends: $-2,915 Mil
GF Value™: $49.32 vs. price of $43.18 (12.4% below fair value)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score
Get the complete analysis for CHGCF
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
